Dublin, Jan. 25, 2019 (GLOBE NEWSWIRE) -- The "Global Vaccine Partnering Terms and Agreements 2010-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering. The Global Vaccine Partnering Terms and Agreements 2010-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains a comprehensive listing of all vaccine partnering deals announced since January 2010, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals. The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners. Available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Therapy target
- Specific technology type
Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Vaccines dealmaking 2.1. Introduction 2.2. Vaccines partnering over the years 2.3. Most active Vaccines dealmakers 2.4. Vaccines partnering by deal type 2.5. Vaccines partnering by therapy area 2.6. Deal terms for Vaccines partnering 2.6.1 Vaccines partnering headline values 2.6.2 Vaccines deal upfront payments 2.6.3 Vaccines deal milestone payments 2.6.4 Vaccines royalty rates Chapter 3 - Leading Vaccines deals 3.1. Introduction 3.2. Top Vaccines deals by value Chapter 4 - Most active Vaccines dealmakers 4.1. Introduction 4.2. Most active Vaccines dealmakers 4.3. Most active Vaccines partnering company profiles Chapter 5 - Vaccines contracts dealmaking directory 5.1. Introduction 5.2. Vaccines contracts dealmaking directory Chapter 6 - Vaccines dealmaking by technology type Chapter 7 - Partnering resource center 7.1. Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking Appendices Appendix 1 - Vaccines deals by company A-Z Appendix 2 - Vaccines deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Vaccines deals by deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination Appendix 4 - Vaccines deals by therapy area Anaesthetics Cardiovascular Central Nervous System Dental Gastrointestinal Hematology Immunology Infectives Metabolic Musculoskeletal Oncology Ophthalmics Orphan disease Pediatrics Psychiatry Respiratory Appendix 5 -Deal type definitions For more information about this report visit https://www.researchandmarkets.com/research/f...ccine?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Vaccines
